ArticlePharmaceutical research2017
Biodegradable Poly(ester-urethane) Carriers Exhibiting Controlled Release of Epirubicin.
Article in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 11 citations in OpenAlex.
- Highly Selective Interfacial Route to Eight-Functional Sucrose Methacrylate for Biocompatible Scaffold Fabrication.Polymers · 2026Article
- Biobased polyurethanes for biomedical applications.Bioactive materials · 2021Review
- Photocurable Methacrylate Derivatives of Polylactide: A Two-Stage Synthesis in Supercritical Carbon Dioxide and 3D Laser Structuring.Polymers · 2020Article
- A Novel Delivery System for the Controlled Release~of Antimicrobial Peptides: Citropin 1.1 and Temporin A.Polymers · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to develop the perspective biodegradable poly(ester-urethane) (PUR) carriers based on "predominantly isotactic" and atactic polylactides (PLAs), and poly(ε-caprolactone) (PCL), for the controlled release of epirubicin (EPI).
methodsThe biodegradable PURs containing different soft segments as new and effective carriers of EPI have been obtained. The preliminary studies on toxicity and degradation of obtained polymers, and the release of the EPI from PUR carriers were carried out.
resultsWe found that the kinetic release of EPI from the obtained PUR carriers tested in vitro at 37°C and pH 7.4 was strongly dependent on the kind of the polyesters, used as the soft segment in PURs synthesis. Furthermore, we demonstrated that the EPI was released from various synthesized carriers in a rather regular manner, according to the diffusion-degradation and degradation mechanisms. Importantly, in some cases, the kinetics of the EPI release was nearly zero-order.
conclusionThe results show that the obtained PURs are very effective and perspective carriers and might be potentially applied in the technology of high controlled EPI delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.